S
Sina Bavari
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 353
Citations - 21495
Sina Bavari is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Ebola virus & Virus. The author has an hindex of 69, co-authored 349 publications receiving 18782 citations. Previous affiliations of Sina Bavari include University of Nebraska Medical Center & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
United States FDA's emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future.
TL;DR: Comment on the diagnostic assays for which the FDA has issued emergency authorizations and their fitness for purpose.
Journal Article
Evaluation of ebolavirus glycoprotein Fc fusion protein as a subunit vaccine (P4417)
TL;DR: Preliminary data indicates that EBOVgp-Fc induces neutralizing antibodies and recall CD8+ T-cell immunity, as assessed by the production of IFNγ and TNFα in PBMC.
Journal ArticleDOI
Nonhuman transferrin receptor 1 is an efficient cell entry receptor for ocozocoautla de espinosa virus
Yíngyún Caì,Shuĭqìng Yú,Steven Mazur,Lián Dŏng,Krisztina Janosko,Téngfēi Zhāng,Marcel A. Müller,Lisa E. Hensley,Sina Bavari,Peter B. Jahrling,Sheli R. Radoshitzky,Jens H. Kuhn +11 more
TL;DR: It is found that the OCEV glycoprotein mediates entry into grivet and bat cells through transferrin receptor 1 (TfR1) binding but that OCEv glycop protein precursor (GPC)-pseudotyped retroviruses poorly entered 53 human cancer cell lines.
Journal ArticleDOI
New 9-aminoacridine derivatives as inhibitors of botulinum neurotoxins and P. falciparum malaria •
Mikloš Tot,Dejan Opsenica,Milena Mitrić,James C. Burnett,Laura Gomba,Sina Bavari,Bogdan A. Šolaja +6 more
TL;DR: With respect to the antimalarial activity, the adamantane acridines were the most potent derivatives, indicating that an adamantyl group is a better carrier than a steroidal motif for this indication.
Patent
Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof
TL;DR: In this paper, a pharmacophore model for inhibiting Botulinum neurotoxin A metalloprotease activity is presented, which consists of a first plane A, a second plane B, a first hydrophobic moiety C, another hydrophilic moiety D and a positive ionizable substituent E.